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Hot melt extrusion (HME) is a widely used manufacturing process for pharmaceutical solid 
dispersions. The complexity of the HME formulations and the number of excipients used in 
the process are increasing with the advancement of the relevant knowledge. However, one of 
the areas that are still significantly lacking understanding is the control of internal 
microstructure of extrudates. Internal microstructure, consisting of voids, in hot melt extruded 
amorphous solid dispersions is often observed without the causes having been systemically 
investigated in the literature. In this study, we investigated a range of factors that 
demonstrated their impacts on the formation of the voids. These include the effect of the 
types of the materials (i.e. drug, polymer and additive) used in the formulation, the quantity 
of the drug and the additives used, the key extrusion processing parameters, the type of 
extruder, and the drying of the raw materials prior to extrusion. The results indicate that the 
appropriate viscosity and the presence of phase-separated particulates are essential for the 
formation of the voids. The particulates act as nuclei for the entrapped gas bubbles and the 
viscosity of the mixture during extrusion governs the collapse/escape of the bubbles. To 
minimise void formation, the results of this study indicate that slow screw speed, low 
moisture content of the raw materials, fewer particulates and the addition of lubricants, such 
as low melting lipid excipients, could be beneficial. This study systematically examines the 
mechanism of void formation in HME extrudates and generates new strategies that can be 
used to manage such void formations.  
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Hot melt extrusion (HME) has been increasingly used in the large-scale manufacturing and 
lab research of producing amorphous solid dispersions. In addition to the active 
pharmaceutical ingredient and the matrix polymer, additives such as plasticizers are often 
used in HME formulations. Most plasticizers are miscible with the polymer, thus can form a 
single-phase amorphous dispersion (Solanki et al., 2019, Snejdrova and Dittrich, 2012, 
Balogh et al., 2014, Maru et al., 2011). However, recently a number of studies reported the 
use of additives, such as disintegrants and other particulate excipients that form a separate 
phase to the drug dispersion (Fukuda et al., 2006, Alqahtani et al., 2020, Deng et al., 2013, 
Krupa et al., 2017, Sadia et al., 2018, Sadia et al., 2016, Crowley et al., 2004). Occasionally, 
voids were observed in extrudates (Alqahtani et al., 2020, Alshafiee et al., 2019, Fukuda et 
al., 2006, Martinez-Marcos et al., 2016, Almeida et al., 2011, Crowley et al., 2004). We 
specifically term such structural features as voids rather than pores because they typically are 
isolated pockets in the interior of the extrudates and they are not, in most cases, apparent on 
the surface of the extrudates. The formation of such voids in the extrudates can potentially 
have significant impact on the physical stability and drug release performance due to their 
high internal surface area. As an example, in our previous study, a range of additives was 
used to modulate the drug release rate of HME extrudates containing carbamazepine (CBZ). 
With 5% w/w loading of these additives, the extrudates exhibited cavitated internal void 
microstructure (Alqahtani et al., 2020). It was observed that the extrudates with cavitated 
interiors exhibited accelerated release rates in comparison to the binary polymer-drug solid 
dispersion (Alqahtani et al., 2020). Therefore, a fuller understanding of why such voids form 
and how to control them is important to the field of pharmaceutical HME. To the best of our 
knowledge, there is no study in the literature that has systemically investigated the origin of 
formation of such internal void structures. The aim of this study was to use a range of model 
 4 
systems to systemically address this question with a clear focus on examining the factors that 
could induce the formation of such cavitated internal microstructure. 
 
We hypothesise that voids in the extrudate are formed by bubbles that are held in place when 
the extrudate solidifies. The bubbles may be formed either by nucleation by residual particles 
(as the nuclei) in the extruding material or by evaporation of water from water containing 
particulates. The stability of the bubbles and their survival as cavities will depend on the 
conditions of extrusion. In this study, we report the detailed investigation into the factors that 
affect the formation of the voids which leads to our hypothesis of the origin of these voids. 
The factors studied include the effect of the types of the materials (i.e. drug, polymer and 
additive) used in the formulation, the quantity of the drug and the additives used, the key 
extrusion processing parameters, the type of extruder, and the drying of the raw materials 
prior to extrusion. The results bring new insights into the control strategies of void formation 
in the pharmaceutical HME extrudates.  
 
Materials and methods 
Materials 
Carbamazepine (CBZ) and felodipine (FDN) were purchased from Molecula (Darlington, 
UK). According the melting point (193 °C) and the PXRD diffraction pattern, the crystalline 
CBZ used for the extrusion experiments is the polymorphic form III (Grzesiak et al., 2003, 
Caliandro et al., 2013). Hydroxypropyl methylcellulose acetate succinate (HPMCAS-LF) 
with the substituent ratios of –CH3, -CH2CH(CH3)OH, -COCH3, and –COCH2CH2COOH 
being 1.87, 0.25, 0.48, and 0.37 average number/glucose ring unit was donated by Shin-Etsu 
Chemical Co. Ltd. (Tokyo, Japan). Poly(vinyl)caprolactam–poly(vinyl)acetate–
poly(ethylene)glycol graft co-polymer (Soluplus®), dimethylaminoethyl methacrylate-co-
 5 
polymer (Eudragit® E PO) and sodium starch glycolate (NaSG) were received as generous 
gifts from BASF (Ludwigshafen, Germany), Evonik (Darmstadt, Germany) and Roquette 
(Lestrem, France), respectively. Gelucire 50/13, crosscarmellose sodium (CNa) and 
Crosspovidone (Polyplasdone-XL) (CP) were supplied by Gattefossé (Saint-Priest, France), 
IMCD UK Ltd (Sutton, UK) and Ashland (Limavady, UK), respectively. Maltodextrin (MD) 
and α-lactose monohydrate were purchased from (Sigma Aldrich, UK). 
 
Preparation of HME filaments 
All formulations listed in Table 1 (except H-NaSG (EL)) were prepared using a co-rotating 
twin screw Haake Minilab extruder (Thermo Fisher, Karlsruhe, Germany). The composition 
of the formulations used for each formulation were summarised in Table 1. All HME 
formulations were extruded at 150 °C with 5 min retention time and at a screw speed at 100 
rpm. Clear effects of the process and the addition of NaSG on the void formation were 
observed for H-NaSG formulation. Therefore H-NaSG is the base formulation of this study 
and was used to compare the impact of the screw speed and the different scales of extruders 
on the void formation. When the effects of screw speed on the void formation were studied, 
50 and 150 rpm screw speed were also used to extrude H-NaSG formulation. The average 
extrusion torque value during the retention period was recorded for each experiment. 10 
grams of the materials were accurately weighed then premixed using mortar and pestle for 5 
minutes. For each extrusion experiment, 7 g of the powder mixture was fed manually into the 
extruder.  
 
In order to investigate the impact of the extruder on the void formation, a larger scale 
extruder (EuroLab 16, Thermo Fisher, Darmstadt, Germany) was used to extrude the H-
NaSG (EL) formulation at a screw speed of 100 rpm and the detailed processing parameters 
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are shown in Table 2. A circular die of 1.75 mm diameter was used and the extruded strands 
were guided onto a conveyer belt and collected continuously.  
 














H 100 - - - 
HG 80 - - 20 
H20 80 20 - - 
HG20 60 20 - 20 
H-NaSG 75 20 5 (NaSG) - 
H-NaSG (EL)* 75 20 5(Na SG) - 
HG-NaSG 60 20 5 (NaSG) 15 
H30 70 30 - - 
H-NaSG30 65 30 5 (NaSG) - 
H50 50 50 - - 
H-NaSG50 45 50 5 (NaSG) - 
H-CP 75 20 5(CP) - 
HG-CP 60 20 5 (CP) 15 
H-CNa 75 20 5 (CNa) - 
HG-CNa 60 20 5 (CNa) 15 
H-LM 75 20 5 (LM) - 
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HG-LM 60 20 5 (LM) 15 
H-MD 75 20 5 (MD) - 
HG-MD 60 20 5 (MD) 15 
H-2NaSG 78 20 2 (NaSG) - 
H-7NaSG 73 20 7 (NaSG) - 
Sol-30 70 (Soluplus) 30 - - 
Sol-50 50 (Soluplus) 50 - - 
EPO-30 70 (EPO) 30 - - 
EPO-50 50 (EPO) 50 - - 
H-FDN 75 20 (FDN) 5 - 
*This sample prepared on the Eurolab 16 extruder 
Table 2: Temperature settings of the extrusion process using Eurolab 16 
HME 
Zones 
1 2 3 4 5 6 7 8 9 10 
°C 25 50 80 130 150 150 150 150 150 150 
 
Thermogravimetric analysis (TGA)  
TGA 5500 discovery series (TA Instruments, Newcastle, USA) was used to test the moisture 
content of the raw materials prior to the extrusion experiments. 5–7 mg of each ingredient 
were loaded into the instrument and a temperature program of 10 °C/min was used, followed 
by an isothermal period of 10 min at 105 °C. Trios (TA Instruments, Newcastle, USA) 
software was used to analyze the acquired results. 
 
Powder X-ray diffraction (PXRD)  
XRPD was performed to determine the crystallinity of raw materials, physical mixtures, and 
extruded formulations using a Thermo ARL Xtra X-ray diffractometer (Thermo Scientific, 
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Switzerland) operated with CuKα radiation, generator voltage at 45 kV and the current was 
40 mA. The angular scan range of 5 – 60° was operated with a (2θ) scan type, 4 s/step 
scanning rate and the step size was 0.01°.  
 
Differential scanning calorimetry (DSC) 
The DSC experiments were carried out using a TA Universal Q2500 Discovery series DSC 
(TA Instruments, Newcastle, DE, United States) to characterise the raw materials and HME 
extrudates. A heating rate of 10 °C/min was used from 25 to 210 °C with 50 ml/min nitrogen 
purge flow. The sample weights in the range of 2-3 mg were used for all samples. TA 
standard crimped pans and lids were used for all measurements as well as Trios software for 
analysing the obtained results. 
 
Scanning electron microscopy (SEM) 
Zeiss EVO HD15 Scanning Electron Microscope built with Lanthanum Hexaboride LaB6 
emitter (Zeiss Microscopy GmbH) and JSM 5900LV Field Emission Scanning Electron 
Microscope (Jeol Ltd., Japan) equipped with a tungsten hairpin electron gun were used to 
study the surface microstructure of the formulation extrudates. The samples were coated with 
gold using a Polaran SC7640 sputter gold coater (Quorum Technologies, city, country) prior 
to imaging. 
 
X-ray microcomputed tomography (XμCT) 
X-ray microcomputed tomography (XμCT) measurements were performed on the different 
extrudate samples using a Skyscan 1172 instrument (Bruker, Antwerp, Belgium) to 
investigate their microstructure characteristics and to visualise the distribution of the different 
ingredients, such as the additive particles, in the extrudates. The XμCT measurements were 
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conducted using a cone-beam configuration without applying any filter.  The 3D imaging of 
the sample was performed by rotating the sample over 180o with an angular rotation step of 
0.4o, and collecting the shadow projected images of the sample at an isotropic voxel 
resolution of 4.46 μm and an exposure time of 350 ms. 7 frames were averaged per position. 
Reconstruction of the projected images was then conducted using NRecon software (Bruker, 
Version: 1.7.4.2) to acquire cross-sectional images of the different extrudate samples. 
DataViewer software (Bruker, Version: 1.5.3.4) was used to visualise and align the 
reconstructed images of the samples. The reconstructed images were further analysed using 
Avizo software (FEI Company, Hillsboro, Oregon, USA, Version: 9.4.0) to create 3D models 
of the extrudate samples. ImagJ software version 1.52e was also used to measure the 
pore/void diameter using the reconstructed images of the extrudate samples. For each 
formulation, two separate samples were tested and the XμCT data were collected and 
analysed.  
 
In vitro drug release studies 
All in vitro drug release studies were carried out using the USP rotating basket method 
(Copley CIS 8000, Copley Scientific) under sink conditions operating at 100 rpm rotation 
speed with 900 mL of either HCl dissolution medium (pH 1.2) or pH 6.8 phosphate buffer 
saline (PBS) maintained at 37 ± 0.5 for each test. Two-stage experiments were performed for 
all dissolution tests to mimic the physiological environment of gastro-intestinal tract. After 2 
hours of dissolution in HCl at pH 1.2, the extrudates were removed and the dissolution 
medium was changed to PBS at pH 6.8. Accurately weighted extrudates containing 
approximately of 10 mg of CBZ were used in 900 ml medium to ensure sink conditions. 3 ml 
of the dissolution media were withdrawn from each vessel and filtered through 0.45 μm 
filters (Minisart Sartorius, Goettingen, Germany) and sampled at predetermined time 
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intervals. After each sampling, 3 ml of fresh pre-warmed media were replenished to the 
dissolution vessel. The samples were analysed using a UV–VIS spectrophotometer 
(PerkinElmer Lamda XLS, USA) at 285 nm. All measurements were performed in triplicate. 
 
Statistical analysis 
Statistical analysis was conducted using Graphpad Prism 7 statistical analysis software by the 
independent Student’s T test for comparison of two groups, and one-way ANOVA for 
multiple groups. All the data are presented as the mean ± SD. P values of < 0.05 were 
considered statistically significant. In all the figures *** is used to indicate P<0.001, ** is 
used to indicate P<0.01, and * is used to indicate P<0.05. 
 
Results and discussion 
The formation of the interior void structure in HME extrudates 
As seen in Figure 1, except the H-CP and its placebo extrudates, the rest of the formulations 
all exhibit an interior with voids. From the previous study, it was confirmed by the DSC 
results that CP is miscible with HPMCAS and CBZ (with 20% drug loading) and forms a 
single-phase solid dispersion after HME (Alqahtani et al., 2020). As seen in Figure 1, the 
phase separated additive particles can be identified in both placebo and drug loaded 
extrudates containing CNa, NaSG, LM and MD. However, it is obvious that without the 
addition of CBZ, the placebo extrudates are either void-free or have much lower density and 




Figure 1. SEM images of the cross-sections of the samples showing the effects of additives 
on the void formation in the interior of the extrudates. (The additive particles are highlighted 
by the red arrows in each image) 
 
XμCT allows the detection of the additive particles when they contain either Na or Ca, which 
have higher atomic mass than the atoms of HPMCAS and the drug. The colour coding is used 
to visualise the additive particles in the extrudates (individual images with enhanced 
resolution can be found in the Supplementary Information). As seen in Figure 2, the 
atomically denser additive particles can be seen as the red dots showing in the XμCT images. 
This is particularly evident in the case of H-NaSG and H-CNa. The XμCT analysis of the 
extrudates confirms that the additive particles are mostly located at the surface of the voids. 
The voids often have a distorted spherical shape. Both SEM and XμCT results confirm that 
the voids are not interconnected, but that the individual voids are present in isolation. These 
results indicate that the co-existence of the drug and the additives are essential for the 
formation of the voids inside the extrudates. The fact that the single-phase dispersion H-CP 
extrudates are void-free indicates that the additive particles play an important role in the 
formation of the voids. We hypothesis that the possible factors involved in void creation are 
moisture, particulate additives, drug, viscosity, extruder conditions. In the following sections 
we investigate these factors systematically. 
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Figure 2. Cross-sections (top) and 3D visualisation (bottom) of the XμCT images of the 
extrudates with additives. The matrix of the polymer-based extrudates are in blue and the red 
dots embedded in the blue matrices of H-CNa and H-NaSG are the CNa and NaSG particles. 
The higher atomic density of sodium in CNa and NaSG than the polymer matrices increased 
the contrast and allowed the identification of these particles in (a)-(d). (Enlarged individual 
images can be found in the Supplementary Information)  
 
Effect of moisture contents of the raw materials 
Both HPMCAS and CBZ contained less than 1% (w/w) moisture. The moisture contents of 
the additives were measured using TGA and the results are summarised in Figure 3a. The 
additives all carried 3-7.5% (w/w) moisture prior to extrusion, thus it is reasonable to 
hypothesis that the moisture contents of the raw material may have an effect on the void 
formation. As the extruder is well ventilated, any volatile solvent from the feed powder mix 
should be easily eliminated during the heating and mixing process of the extrusion, unless the 
molten mass in the extruder was too viscous to allow the escape of the entrapped gas. This is 
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supported that the data shown in Figure 3b and 3c indicating no clear correlation between 
the amount of moisture content with the void diameter. This indicates that the moisture 
content of the particles of the additives is not the sole cause of the formation of the voids. 
Nevertheless, it is clear that in order to reduce the number and density of voids, reducing the 
initial moisture in the raw materials may be desirable. When the raw materials of the 
additives were dried for 6 hours at 105 °C, both void size and void density in the extrudates 
were dramatically reduced, as seen in Figure 4.  
 
Therefore, we hypothesise that during the extrusion process, the particles of the additives are 
the source of water that forms vapour which in turn results in the voids that can be detected in 
the finished extrudates. Since dry particles produce some voids it is also likely that they act as 
nuclei for dissolved air. These gas bubbles are entrapped, i.e. they cannot escape, due to the 
high viscosity of the mix and thus remain as voids that can be observed in the extrudates after 
cooling. Therefore, the effects of viscosity of the formulations were investigated in the 





Figure 3. Correlation between the void diameter and the moisture contents in the raw 
materials. (a) Moisture contents of raw materials measured by TGA; (b) pore diameters of the 
HME extrudates with additives; (c) pore diameters of HME extrudates with Gelucire 50/13 
and the additives. The pore diameters in (b) and (c) were measured using the XμCT data. 
Representative XμCT images of the cross-section of each formulation are shown at the 
bottom panels of (b) and (c). As the extrudates of H-CP and HG-CP are completely void-free, 
no XμCT images are shown here. The data are represented as the mean ± SD, n = 2  
(***P<0.001, ** P<0.01, and *P<0.05). 
 
 
Figure 4.  SEM images of the cross-sections showing the effect of drying of the raw 
materials on the formations of the voids. 
 
Effect of viscosity  
During the HME process, the recorded torque value is a direct reflection of the viscoelastic 
properties of the material being processed in the extruder. Figure 5 shows the recorded 
torque values of all the formulations with and without drug (Figure 5a) and with and without 
Gelucire 50/13 (Figure 5b) in the formulations. The binary mixture of HPMCAS and 20% 
CBZ (H20), the drug is completely solubilised in the polymer and forms an amorphous solid 
dispersion (Alqahtani et al., 2020). With a lower glass transition temperature (Tg) of 56 °C 
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compared to HPMCAS (with a Tg of approximately 120 °C), CBZ exhibited a clear 
plasticisation effect on the polymer and reduce the viscosity of the mixture in the extruder 
which led to the significant reduction in torque required for extrusion in comparison to 
HPMCAS alone. As seen in Figure 6a-c, the binary extrudates without the particulate 
additives, with increasing the drug load from 20% to 50% w/w, the density of the voids 
increases. This indicates that reduced viscosity to a certain level could potentially favour the 
formation of the voids. In general terms, if the air bubbles were entrapped in a viscous liquid, 
increased viscosity of the liquid would make the escape of the air bubbles (using velocity of 
the bubble as the measure) more difficult (slower velocity of movement in the liquid) 
according to the Stokes formula (Smirnov and Berry, 2015, Landau and Lifshitz, 1987). 
However in the case of this study, the results indicate that a balance is required: if the 
viscosity is too high bubbles won’t grow and if it is too low bubbles will grow to burst or 
escape to the surface. Since both polymer type and drug loading may affect viscosity of the 
molten mixture in the extruder, both may affect cavity formation by changing viscosity. This 
result agrees well with the similar void-forming phenomena reported in the literature 
(Alshafiee et al., 2019, Martinez-Marcos et al., 2016, Fukuda et al., 2006).  
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Figure 5.  The average torque values (%) recorded during the hot melt extrusion process of 
the formulations (a) without and (b) with Gelucire 50/13. The data are represented as the 
mean ± SD, n = 3  (***P<0.001, ** P<0.01, *P<0.05 and (***) indicates that the torque 
value is statistically significantly (with a P<0.001) different from the rest of the formulations 
in the group). 
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Figure 6. SEM images of the cross-sections showing the combination effect of drug loading 
and addition of the additive on the formation of the voids. (a) H20; (b) H30; (c) H50; (d) H-
NaSG; (e) H-NaSG30; (f) H-NaSG50; g) H-FDN.  
 
In addition to the differences observed in the numbers of voids in the extrudates with 
different drug loadings, the diameters of the extrudates also increases with increasing the 
drug content and the screw speed, as shown in Figure 7. The larger diameter of the 
extrudates with higher drug contents (both with and without the particulate additives) may be 
a result of the higher numbers of voids than the ones with lower drug loading systems 
(Figure 7a). At the extruder die orifice, the sudden pressure drop allows the gas in the voids 
to expand in volume. This leads to the expansion of the diameter (often referred as “die 
swell”). Higher screw speed provides higher shear stress and internal pressure in the extruder 
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which leads to more die swell. However this did not lead to significant difference in the 
diameter of the extrudates produced by different screw speeds, as observed in Figure 7b.  
 
Figure 7. The summaries of the extrudates diameters: (a) The extrudates containing 20, 30, 
50 % w/w CBZ loaded in HPMCAS (H20, H30, H50) and 20, 30, 50 %w/w CBZ loaded in 
HPMCAS with 5 %w/w NaSG (H-NaSG, H-NaSG30, H-NaSG50); (b) HPMCAS-CBZ 
binary extrudates diameters produced using screw speeds of 50, 100 and 150 rpm. The data 
are represented as the mean ± SD, n = 3 (*P<0.05). 
 
It is noted that very few small particles can be seen in the interior of the extrudates with 30% 
drug loading. As seen in Figure 8, the DSC results of the 30% drug loaded extrudates show a 
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Tg at approximately at 65 °C which is lower than the theoretical calculated Tg of the binary 
mixture according to Gordon-Taylor equation; whereas the Tg of the 50% drug loaded 
extrudates (H50) is in the same region of the amorphous CBZ, which is around 56 °C, 
indicating the presence of a significant amount of amorphous drug. The PXRD results 
confirm that 30% drug loaded extrudates are largely amorphous and 50% drug loaded 
extrudates contain a significant amount of crystalline CBZ. These results indicate that 30% 
drug loading approaches the saturation of the solubility of the drug in HPMCAS and 50% 
binary extrudates are supersaturated with crystalline drug. In a way similar to the dried phase 
separated additives, these un-dissolved drug particles could act as the nuclei of the gas 
bubbles and facilitate the formation of the voids. Therefore, in the case of 50% drug loaded 
binary extrudates, viscosity is not the sole factor causing the voids.  
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Figure 8. (a) DSC and (b) PXRD results of the binary extrudates with the drug loading 
ranging from 20-50% w/w.  
 
As seen in Figure 5a, the addition of 5% (w/w) particulate additives of CNa, NaSG, LM, and 
MD resulted in further significant reductions of the viscosity and subsequently the torque 
values of the extrusion process in comparison to the binary extrudates of H20. This was not 
the case for H-CP. As discussed earlier, H-CP forms a single-phase dispersion because CP is 
miscible with HPMCAS and CBZ at the proportion used in the formulation. CP was 
homogenously mixed and formed a single-phase molecular dispersion with HPMCAS and 
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CBZ. We speculate that any moisture carried by the additive would be homogeneously 
distributed and there are no nucleating sites for bubble formation. In the case of the other 
phase-separate particulate additives, water is concentrated locally in the particle and the 
release of a relatively large amount in a small region causes bubble formation. When the 
moisture turns to steam, it generates a significant volume of gas around each particle 
(approximately 1 cm3 of gas per g of matrix depending on the details of temperature and 
pressure).  
 
A significant further reduction of the torque was observed when Gelucire 50/13 was added to 
the binary and ternary formulations, as shown in Figure 5b. This may contribute to the 
remarked reductions on both the void size and void density seen in Figure 3c. Gelucire 50/13 
is a semi-crystalline lipid-based additive that is not miscible with HPMCAS. This is 
confirmed by the measureable melting of Gelucire in the DSC results of the extrudates 
(Alqahtani et al., 2020). At the extrusion temperature used in this study, the melt viscosities 
of fats and lipids are typically much lower in comparison to polymers, such as HPMCAS. As 
the molten Gelucire 50/13 is phase separated from HPMCAS, during the thermal extrusion, 
Gelucire acts as a ‘lubricant’ of the molten mixture and reduces the overall melt viscosity of 
the system in the extrusion. This facilitates the escape/collapse of entrapped gas bubbles and 
leads to fewer and smaller voids. The possibility of molten Gelucire coating the additive 
particles may also reduce the number of the nucleus sites of the gas bubbles which may 
contributed to the significantly fewer voids with smaller diameters in the Gelucire containing 
extrudates seen in Figure 3c.  
 
With the model particulate additives, 5% NaSG (w/w), increasing the drug loading should 
lead to reduced viscosity during extrusion due to the drug’s plasticisation effect on 
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HPMCAS. We observed a reduction of the size of the voids, but this coincided with increased 
density of the voids (Figure 6e). This could be attributed to the break-up of each large void 
into a number of small satellite voids when the viscosity is low (but still sufficient to entrap 
the bubbles). Therefore, the results suggest that there is a critical minimal viscosity of the 
mixture that above this viscosity the mixture would be able to retain the bubbles and allow 
the shape deformation, but without collapse of the bubble.   
 
The H-NaSG50 extrudates (with 5% NaSG and 50% drug load) are a much more complex 
case. The 50% mixture is saturated since 30% drug is the solubility limit. Hence the viscosity 
of the mixture should be similar to that of the 30% mixture which can form voids. However 
there are more particles in the 50% mixture due to un-dissolved drug. Nucleation from these 
particles results in more gas bubbles formed hence the 50% extrudates show a larger number 
of voids. 
 
In order to eliminate the possibility that the formation of voids in the extrudates is drug 
specific, another model drug, felodipine (FND), that has a slightly lower Tg than CBZ, was 
tested. As seen in Figure 6g, interior voids in H-FDN extrudates are still clearly visible. Solid 
particulates can be seen at the interface of the voids. This confirms that the void formation is 
not drug specific and the presence of phase separated solid particulates is essential for void-
forming.  
 
To further confirm that the void-forming is not polymer specific and to prove that the 
viscosity of the mixture in the extruder is one of the key factors determining the formation of 
the voids, two different polymers with different reported melt viscosity were used. Binary 
extrudates of CBZ with Soluplus and Eudragit® E PO, two widely used HME polymers, were 
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prepared without NaSG. At the HME temperature used in this study (150 ºC) the complex 
viscosity measured is in the order of Eudragit® E PO (103.1 Pa.s) ≈ Soluplus (103.8 Pa.s) 
<HPMCAS (105.2 Pa.s) (Parikh et al., 2016, Meena et al., 2016, Gupta et al., 2016). The 
extrudate diameters of H30 ad H50 are significantly higher than the Eudragit® E PO and 
Soluplus based extrudates (data shown in Supplementary Information). As seen in Figure 9, 
both Sol-30 and EPO-30 show either no void or very low numbers of small voids compared 
to the ones observed in H30 extrudates, despite the clear observation of the presence of 
recrystallized drug particles (highlighted by the red arrow). The DSC and PXRD data shown 
in Figure 10 confirmed these being recrystallized drug particles. From the melting point and 
the PXRD diffraction patterns, it is clear that the recrystallized drug particles are in different 
polymorphic form (form I) from the starting material which is CBZ form III (Grzesiak et al., 
2003, Caliandro et al., 2013). This indicates that 30 and 50% drug loadings formed 
supersaturated solid dispersions for both Soluplus and Eudragit EPO. This confirms that a 
sufficient level of viscosity is important for the void formation and that when the viscosity is 
below the critical minimal viscosity void formation can be eliminated altogether even the 
presence of solid particles.  
 
With increasing the drug loading to 50%, a significant amount of recrystallized drug particles 
can be observed in all formulations. Consequently, voids are observed in both H50 and EPO-
50 extrudates. However, it is interesting to see that the Sol-50 shows no voids, despite the 
recrystallized drug particles being visible. We speculate that this may be due to the low 
interfacial tension between Soluplus and the drug particles. Soluplus is a surface-active 
polymer that may be easier to be spread and ‘wet’ the surface of the drug particles. However, 
this is speculative and further experiments are required which are out of the scope of this 
study.   
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Figure 9. SEM images of the cross-sections of the extrudates showing the effect of matrix 
polymer type and drug loading on the void formation. All formulations were additive-free 
(red arrows indicate the presence of possible recrystallized drug particles). 
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Figure 10. DSC (a and c) and PXRD (b and d) data of Sol-30, Sol-50 and EPO-30 and EPO-
50. 
Effect of process parameters 
As the formation of the voids is a result of the extrusion process, it is important to examine 
the effect of extrusion operation on the void formation. The bubble entrapment and collapse 
in the viscous polymer-drug mixture during the extrusion can be affected by the external 
perturbations experienced by the bubbles. Similar to complex multi-phase fluid flow, such 
sources of perturbations include the shock generated by the collapse of a neighbour bubble, 
shape deformation caused by the large fluctuations of longitudinal and transverse velocity of 
the mixture that the bubbles are embedded in during the high shear movement of the 
extrusion, and uneven shear experienced by the mixture closer to the surface and beneath the 
surface of the rotating screws (Hann et al., 2018). Based on this, we hypothesise that different 
levels of surface shear would influence the void formation. On the basis of this hypothesis, 
we employed a range of screw speeds to investigate the effect of the combination of the flow 
velocity and shear on the formation of voids. Unfortunately, for a manufacturing process such 
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as HME, it is impossible to separately investigate a single factor in isolation, as increasing 
shear would also lead to a change in fluid velocity. Nevertheless, it should provide new 
insights into the control strategy of the void formation.  
 
As seen in Figure 11, the screw speeds used during HME show a clear effect on the void 
diameter and the void density. At slower screw speeds, fewer voids were generated (Figure 
11a). These voids were much smaller in diameter in comparison to the voids that were 
observed in the extrudates manufactured at 100 rpm screw speed. It is also noted that most of 
the well-defined voids (30-50 µm in diameter) are mainly located close to the edge of the 
extrudates. The small voids (10-20 µm in diameter) were scattered across the interior of the 
extrudates often showed a furrow tail. All these furrows are oriented in the same direction, 
which could well coincide with the rotation direction of the screw. Increasing the screw speed 
from 100 to 150 rpm resulted in a reduction of the void diameter by about half and an 
approximate 200% increase of the void density (Figure 11c). If the viscosity of the mixture 
was sufficient to hold the bubbles, the faster screw rotation could cause the deformation of 
the void shape and the breakage of a large void into smaller voids. This could explain the 
observed increased density and reduced void size. The differences between the mean void 
diameters of the extrudates processed by the three screw speeds are significantly different 
(Figure 11e), indicating the screw speed has a profound impact on the void formation. The 
results suggest that a slow screw speed needs to be selected to avoid void formation during 
extrusion.  
 
Often lab scale bench top extruders are built with much shorter screws in comparison to 
industrial scale extruders. Therefore, the same formulation (H-NaSG) was prepared using a 
larger extruder (H-NaSG(EL)), EuroLab 16, to ensure that void formation is not an artefact of 
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the small lab scale extruder. As seen in Figure 11d, although the overall diameters of the 
extrudates are larger than the extrudates produced by the bench top extruder, the void 
diameters are not statistically significantly different from the ones produced by the small 
bench top extruder (Figure 11f). The difference in the diameter of the extrudates is due to the 
different size of die used on the large and bench top extruder. This result confirms the 
porosity is intrinsic to the formulation and the process, but not the scale of the extrusion 




Figure 11. SEM images of the cross-sections of the interior structures of H-NaSG extrudates 
produced using a) 50 rpm; b) 100 rpm; c) 150 rpm screw speed on a Mini-lab twin screw 
extruder and d) H-NaSG (EL) produced by a Eurolab-16 Extruder at 100 rpm screw speed. 
The data are represented as the mean ± SD, n = 3  (***P<0.001). 
 
Effect of porosity on drug release 
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If the extrudates were to be used as the dosage form (such as strands or short pellets), it is 
important to understand the impact of the interior voids on the drug release behaviour of the 
formulations. As seen in Figure 12, whatever the method used to induce void formation 
(either by changing the loading of the particulate additives, or the drug loading or the screw 
speed), a clear trend of higher relative void volume leading to a faster dissolution is observed. 
Drug loading shows the most profound impact on the drug release rate with shortening the 
T50 from 15 hours to 3.6 hours when changing the drug load from 20% to 50% (w/w). As 
seen in Figure 6, the extrudates with 50% drug loading have almost a honeycomb structure. 
Due to there high relative void volume, the material density per unit volume of H50 is 
significantly lower than the ones of H20. This may explain the rapid dissolution data. The 
changes in release rates due to changes in screw speed and NaSG loading were less dramatic 




Figure 12. The in vitro drug release (0-2 hours in pH 1.2 simulated gastric pH followed by 
replacement of pH 6.8 PBS as the dissolution media) data of a) extrudates with a loading of 
NaSG ranging from 2-7% w/w (with the insert being the SEM images of 2% NaSG 
extrudates with a lower void density than others) (H-2NaSG, H-NaSG, H-7NaSG); b) binary 
extrudates with a drug loading ranging from 20-50% w/w (H20, H30, H50); c) H-NaSG 
extrudates processed using screw speed ranging from 50-150 rpm.  
 
Figure 13. Void diameter change of H-CNa and HG-CNa during the dissolution process with 
the bottom panel showing the representative reconstructed cross-section images of the XμCT 
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data of the H-CNa and HG-CNa extrudates taken at different time intervals during the 
dissolution test.  
 
In order to further confirm the role of the voids playing in facilitating the dissolution process, 
the void size and distribution were monitored during the dissolution process. As seen in 
Figure 13, despite with or without Gelucire 50/13, the void diameters of the extrudates with 
the particulate additives are fairly consistent throughout the dissolution process. This 
indicates that a surface erosion process dominates the dissolution process. This is confirmed 
by the SEM results of the extrudates. As seen in Figure 14, after 2 hours of the dissolution, 
the surface of the extrudates with interior voids all show the full exposure of open voids at 
the surfaces. The cross-section images of the extrudates show little visible changes in 
comparison to the fresh samples (Figure 1). This is good evidence suggesting the surface 




Figure 14. SEM images of the surfaces and the cross sections of the extrudates after 2 hours 
of the dissolution tests in pH 6.8 PBS followed by drying (the crusty texture of the surfaces is 
a results of salt crystallisation of the dissolution media used during drying). 
 
Conclusion 
This study explored the origin of the void formation in HME extrudates primarily produced 
by lab scale hot melt extruders and investigated the factors that can be used to manipulate the 
size and number density of such voids. The results indicated that the viscosity and the 
presence of phase-separated particulates are essential for the formation of the voids. It is 
likely that the particulates act as nuclei for bubbles forming from entrapped air and, if they 
contain moisture, steam formed from the moisture released during processing. A threshold 
level of the viscosity of the mixture controls the collapse/escape of the bubbles. Therefore in 
order to minimise void formation, the results of this study indicate that low moisture content 
of the raw materials, low proportion of particulates and the addition of lubricants, such as low 
melting lipid excipients, could be beneficial. Slow screw speed is also preferred for reducing 
the formation of the voids. This study systematically reported the mechanism of void 
formation in HME extrudates and generated new insights into the strategies that can be used 
to manage such void formations.  
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